fda safety communication semaglutide vision loss naion 2025 The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of data showed. Added Ozempic & Wegovy Vision Loss

Its targeted approach makes it a vital tool in the repertoire of eyelid rejuvenation techniques, offering a tailored solution for more complex or advanced cases of eyelid drooping

Its easy to overlook the finer points of peptide handling

Your provider will review your health history and goals before recommending any protocol

Foundayo is contraindicated in patients with a family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Before starting GLP-1 treatment , inform your GP about: Current or previous anxiety disorders , including generalised anxiety disorder, panic disorder, social anxiety, or health anxiety Other mental health conditions such as depression, eating disorders, or obsessive-compulsive disorder Current psychiatric medications , as weight loss may affect medication requirements though GLP-1 medications themselves have few direct drug interactions Previous experiences with weight loss or diabetes medications and any associated mood changes Your support network and coping strategies for managing stress and anxiety Your GP can help establish baseline mental health status and develop a monitoring plan